91���Ѽ

CU Boulder Today—In 2016, Pfizer began collaborating with Sabrina Spencer, a global leader in time-lapse cell imaging and member of the CU Cancer Center, to study how cancer cells respond to their potent new drugs called CDK2 inhibitors.

CU Boulder researchers have identified a surprising new player in ALS (amyotrophic lateral sclerosis)—an ancient, virus-like protein. With funding from the ALS Association, the National Institutes of Health, and Venture Partners at CU Boulder, Alexandra Whiteley's lab is now working to understand the molecular pathways involved and to find a way of inhibiting the rogue protein.

NIST—Researchers at the National Institute of Standards and Technology (NIST) and CU Boulder have fabricated a novel device that could dramatically boost the conversion of heat into electricity. If perfected, the technology could help recoup some of

Interesting Engineering—The primary goal of soft robotics is to achieve smooth and complex movement by mimicking the locomotion of soft bodies found in the environment. Researchers at CU Boulder and CU Boulder startup Artimus Robotics are leading innovation with a new type of "artificial muscle" to enable life-like movements.

Say “hello” to the robots of the future: They’re soft and flexible enough to bounce off walls or squeeze into tight spaces. And when you’re done with them, you can toss these machines into a compost bin to decompose.

Scientists from CU Boulder and the National Institute of Standards and Technology (NIST) made an important leap forward in the quest to diagnose disease using exhaled breath, reporting that a new laser-based breathalyzer—born of Nobel Prize-winning technology from CU—powered by artificial intelligence (AI) can detect COVID-19 in real-time with excellent accuracy.

Endpoints News—OnKure Therapeutics has lined up $60 million in a new private funding round, adding to the CU Boulder spinout’s bank account as it works through a Phase II trial. The startup is attempting to create an inhibitor of histone deacetylases, or HDACs, which are DNA-manipulating enzymes that alter how genes get expressed.

Wanted: entrepreneurs ready to launch startups based on innovations created in CU Boulder’s research labs. The Embark Deep Tech Startup Creator is a new program created by Venture Partners at CU Boulder, the commercialization arm of CU, to match business minds outside the university with breakthrough inventions created within its walls.

As a first-generation college student turned molecular biologist, Brian DeDecker imagines a day when humble soybeans beans, which his family has grown for generations, pack a bounty of therapeutic but hard-to-obtain natural compounds.

FDA—Flow imaging software from Theodore W. Randolph's (College of Engineering and Applied Sciences) lab and licensed to SentrySciences to create their ParticleSentryAI product was recently highlighted by the FDA in advancing drug product quality.